Number 3: Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab ...
The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...
Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...
The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...
Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential ...
Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
Number 5: Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback